Efficacy and Safety of Chia Seed Powder, Pea Protein, and Xyloglucan in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Open Access
- 23 February 2025
- journal article
- research article
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 19
Abstract
Background/Objectives: Natural compounds represent novel promising alternative treatments for functional gastrointestinal disorders. This multicenter, double-blind, randomized, placebo-controlled, crossover study aimed to evaluate the efficacy and safety of xyloglucan, pea protein, and chia seed powder (XP + CS) in irritable bowel syndrome with constipation (IBS-C). Methods: Sixty patients received twice-daily XP + CS or placebo for 28 days. Following a 28-day washout period, patients switched to the alternative treatment for another 28 days. Efficacy was evaluated using the Bristol Stool Form Scale; a seven-point Likert scale for abdominal pain, bloating, and discomfort; a Visual Analogue Scale for IBS symptom severity; the quality of life (QoL)-IBS questionnaire; Sickness Impact Profile (SIP) score; and serum zonulin concentrations. Adverse events were monitored throughout the study. Results: Compared to the placebo, XP + CS significantly improved stool consistency (p = 0.04 and p < 0.001 at days 15 and 28, respectively), IBS symptoms (p < 0.001 at day 15), QoL (p < 0.001 from day 15 on), and nearly all SIP domains (p < 0.001 at all time-points). Additionally, XP + CS treatment restored serum zonulin concentrations to within normal ranges by day 15. No serious adverse events were reported. Conclusions: This study provides evidence supporting the efficacy and safety of XP + CS in managing IBS-C symptoms.Keywords
Funding Information
- Devintec SAGL, Switzerland
This publication has 45 references indexed in Scilit:
- Translational evaluation of Gelsectan ® effects on gut barrier dysfunction and visceral pain in animal models and irritable bowel syndrome with diarrhoeaUnited European Gastroenterology Journal, 2024
- Efficacy and Safety of Pea Protein and Xyloglucan Versus Simethicone in Functional Abdominal Bloating and DistensionDigestive Diseases and Sciences, 2023
- Italian guidelines for the management of irritable bowel syndromeDigestive and Liver Disease, 2022
- Constipation, diarrhea, and prophylactic laxative bowel regimens in the critically ill: A systematic review and meta-analysisJournal of Critical Care, 2019
- Updated review of current pharmacological and non-pharmacological management of irritable bowel syndromeLife Sciences, 2018
- Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online QuestionnaireAdvances in Therapy, 2018
- Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble FiberJournal of the Academy of Nutrition and Dietetics, 2017
- Intestinal membrane permeability and hypersensitivity in the irritable bowel syndromePain, 2009
- Intestinal Permeability in Irritable Bowel Syndrome Patients: Effects of NSAIDsDigestive Diseases and Sciences, 2009
- Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac diseaseThe Lancet, 2000